Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

Sairopa

Status and phase: Enrolling; Phase 1

Conditions: Solid Tumor, Adult; Refractory Cancer; Metastatic Solid Tumor

Treatments: Drug: ADU-1805; Drug: Pembrolizumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT05856981

SRP-22C102

Details and patient eligibility

About

This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).

Full description

The study will start with the ADU-1805 monotherapy dose escalation arm following an i3+3 design until the RP2D is defined. The ADU-1805 plus pembrolizumab dose escalation arm, also following an i3+3 design, will start after clearance of the ADU-1805 monotherapy dose level achieving maximum target engagement (e.g. ≥ 90% target engagement) and will continue until the RP2D for the combination is defined.

Enrollment: 90 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female aged ≥18 years
• Signed and dated informed consent form
• Histologically and/or cytologically confirmed diagnosis of metastatic or unresectable solid tumors that are refractory to standard therapy or for which no standard therapy exists
• Measurable disease according to RECIST (Safety Expansion only)
• ECOG Performance status of 0 or 1
• Adequate organ and marrow function

Exclusion criteria

• Patients that suffer from melanoma, brain tumors, glioblastoma, sarcoma and pancreatic ductal adenocarcinoma (PDAC)

• Pregnancy or breast-feeding

• Prior treatment with or receipt of:

  • biological agents, including monoclonal antibodies and immunotherapies, within 28 days prior to the first dose of ADU-1805
  • chemotherapy, targeted small molecule therapy, hormonal therapy or radiation therapy within 21 days prior to the first dose of ADU-1805 and within 42 days for nitrosoureas and mitomycin C.
  • anti-SIRPα or anti-CD47-directed therapy
  • systemic chronic steroid therapy or immunosuppressive therapy within 14 days prior to the first dose of ADU-1805
  • other investigational new drug or investigational device within 28 days prior to the first dose of ADU-1805
  • vaccine containing live virus within 28 prior to the first dose of ADU-1805

• Active untreated brain metastases

• Active infection requiring systemic therapy

• Impaired cardiac function or clinically significant cardiac disease

• Current Grade >2 toxicity related to prior anti-cancer therapy

• History of drug-induced severe immune-related adverse reaction

• Prior severe hypersensitivity to other monoclonal antibodies or ADU-1805 excipients

• Major surgery within defined period

• Diagnosis or positive test of HIV, hepatitis B, hepatitis C, or active tuberculosis

• Allogenic tissue/solid organ transplant

• Any intercurrent illness that is life-threatening or of such clinical significance that it would interfere with the patient's safety or ability to participate in the study

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

90 participants in 2 patient groups

Monotherapy dose escalation, IV, Q3W, multiple dose levels

Experimental group

Description:

ADU-1805 monotherapy dose escalation

Treatment:

Drug: ADU-1805

Combination dose escalation, IV, Q3W, multiple dose levels, pembrolizumab at fixed dose

Experimental group

Description:

ADU-1805 plus pembrolizumab dose escalation

Treatment:

Drug: Pembrolizumab

Drug: ADU-1805